Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Based on the evidence that aripiprazole added to serotonin reuptake inhibitors (SRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD) has reported promising results, the present 16-week, double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of aripiprazole add-on pharmacotherapy on clinical symptoms and cognitive functioning in a sample of treatment-resistant OCD patients receiving SRIs. After clinical and neurocognitive assessments, patients were randomly allocated to receive, in a double-blind design, 15 mg/d of aripiprazole or a placebo. A final sample of 30 patients completed the study. The results obtained indicate that aripiprazole added to stable SRI treatment substantially improved obsessive-compulsive symptoms as measured by changes on the Yale-Brown Obsessive Compulsive Scale total score and subscores (obsessions, P = 0.007; compulsions, P = 0.001; total score, P < 0.0001). Regarding cognitive functions, improvement was observed in some explored areas, such as attentional resistance to interference (Stroop score, P = 0.001) and executive functioning (perseverative errors, P = 0.015). The findings provide evidence that aripiprazole augmentation of SRIs/clomipramine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant OCD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low doses of augmented aripiprazole (10 mg/day) were confirmed to be effective and well-tolerated in treatment-refractory OCD by several RCTs [29,30].”
From Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults (2023) · cites this paper as [29]
In the citing paper
“one such drug, aripiprazole, has already been shown to be effective in augmentation in OCD, with some evidence of efficacy at very low doses (Ercan et al. 2015; Janardhan Reddy et al. 2017; Muscatello et al. 2011; Sayyah et al. 2012; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Muscatello et al. 2011
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“The following instruments were used as primary efficacy measures: Y-BOCS,(37,38) Clinical Global ImpressionYSeverity (CGI-S),(40) and Hamilton Rating Scale for Depression (HDRS).(41) Response to aripiprazole was defined as clinical improvement in the OC component (Q25% decrease in the total YBOCS score).”
MethodThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Wisconsin Card Sorting Test Manual – Revised and Expanded
Heaton, R. K., Chelune, C., Talley, J., Kay, G., & Curtiss, G. (1981) · Medical Entomology and Zoology · Cited by 2,987
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
Greist, J. H. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950130053006 · Cited by 500
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Pallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408 · cited 1×
“However, SRIs have found to be effective as monotherapy in only 40% to 60% of OCD patients, with some patients showing a substantial degree of residual symptoms.(5,6) Within this context, treatment options for patients who incompletely respond to SRIs include switching, augmentation, and novel agent strategies.”
BackgroundThird Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311 · cited 1×
“It has also been suggested that, beyond partial agonism, aripiprazole has a kind of ‘‘functional selectivity’’ on the targeted D2 receptor that is highly dependent on the cellular location of the receptor and influenced by signaling proteins.(50) In animal models, it has been documented that aripiprazole’s partial TAB…”
BackgroundNeuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.5.652 · Cited by 271
Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197
Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 197
Natesan, S., Reckless, G. E., Nobrega, J. N., Fletcher, P. J., & Kapur, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300983 · Cited by 192 · cited 2×
“7% of the aripiprazole group) had a reduction between 25% and 34%, which could be defined as partial response according to the stages of response proposed by Pallanti et al,(45) whereas 4 of them (25% of the aripiprazole group) had a reduction of 35% or greater in Y-BOCS total score, corresponding to a full response.(…”
BackgroundMethodQUALITY OF LIFE IN OBSESSIVE-COMPULSIVE DISORDER
Koran, L. M. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70177-5 · Cited by 184 · cited 1×
“Obsessive-compulsive disorder (OCD) is a chronic and often disabling disorder that affects 2% to 3% of the general population with a major impact on several domains, including social functioning, employment, marriage and family relationships, and socioeconomic status.(1) Serotonin reuptake inhibitors (SRIs) and the tr…”
BackgroundStein, D. J., Bouwer, C., Hawkridge, S., & Emsley, R. A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0306 · Cited by 169
Gao, K., Muzina, D., Gajwani, P., & Calabrese, J. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0902 · Cited by 164
Advantages and disadvantages of combination treatment with antipsychotics
Goodwin, G. M., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., Binder, M. D., Falkai, P., Kapur, S., Leucht, S., Licht, R. W., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.003 · Cited by 164
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena, S., Wang, D., Bystritsky, A., & Baxter, L. R. (1996) · PubMed · Cited by 154
Shapira, N. A., Ward, H. E., MANDOKI, M. W., Murphy, T. K., Yang, M. C. K., Blier, P., & Goodman, W. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.010 · Cited by 154
Neurobiology of Obsessive-Compulsive Disorder:Serotonin and Beyond
Westenberg, H. G. M., Fineberg, N. A., & Denys, D. (2007) · CNS Spectrums · doi:10.1017/s1092852900002479 · Cited by 148 · cited 4×
“Key Words: aripiprazole, serotonin reuptake inhibitors, clomipramine, obsessive-compulsive disorder (J Clin Psychopharmacol 2011;31: 174Y179) Obsessive-compulsive disorder (OCD) is a chronic and oftendisabling disorder that affects 2% to 3% of the general population with a major impact on several domains, including so…”
BackgroundInfluentialThe neurocognitive effects of aripiprazole: an open-label comparison with olanzapine
Kern, R. S., Green, M. F., Cornblatt, B. A., Owen, J. R., McQuade, R. D., Carson, W. H., Ali, M. W., & Marcus, R. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0428-x · Cited by 145 · cited 1×
“To the best of our knowledge, there are no clinical studies addressing the effects of aripiprazole on cognitive functions in OC patients, whereas cognitive-enhancing effects of aripiprazole were observed in schizophrenic patients.(47,48) This is the first double-blind, placebo-controlled study of aripiprazole augmenta…”
ResultSkapinakis, P., Papatheodorou, T., & Mavreas, V. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.07.002 · Cited by 136
The Use of Aripiprazole in Obsessive-Compulsive Disorder: Preliminary Observations in 8 Patients
Connor, K. M., Payne, V. M., Gadde, K. M., Zhang, W., & Davidson, J. R. T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0107 · Cited by 135
Goodman, W. K., Kozak, M. J., Liebowitz, M., & White, K. L. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00003 · Cited by 120 · cited 1×
“The observation that antipsychotics may be useful in patients with refractory OCD is consistent with preclinical evidence suggesting significant interactions between serotonin and dopamine systems in mediating OC symptoms.(49) Aripiprazole displays a receptor-binding profile substantially distinct from both first- and…”
ResultA Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Kaplan, A., & Hollander, E. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.8.1111 · Cited by 108
In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain
Bortolozzi, A. A., Díaz-Mataix, L., Tóth, M., Celada, P., & Artigas, F. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0698-y · Cited by 106
Maina, G., Pessina, E., Albert, U., & Bogetto, F. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.001 · Cited by 101
Obsessive-compulsive disorder: diagnosis and treatment.
Goodman, W. K. (1999) · PubMed · Cited by 93
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
Ipser, J. C., Carey, P., Dhansay, Y., Fakier, N., Seedat, S., & Stein, D. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005473.pub2 · Cited by 93
Kordon, A., Wahl, K., Koch, N., Zurowski, B., Anlauf, M., Vielhaber, K., Kahl, K. G., Broocks, A., Voderholzer, U., & Hohagen, F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318185e735 · Cited by 78 · cited 1×
“Notwithstanding, negative results were reported for risperidone,(20) olanzapine,(21) and quetiapine.(22,23) Antipsychotic augmentation in treatment-resistant OCD is yet well supported by meta-analysis(9,24,25) and by recent reviews,(7,8,10,23,26,27) which tend to confirm the efficacy of this treatment strategy, also p…”
ResultVulink, N. C. C., Denys, D., Fluitman, S. B. A. H. A., Meinardi, J. C. M., & Westenberg, H. G. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04269 · Cited by 75
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder
D’Amico, G., Cedro, C., Muscatello, M. R. A., Pandolfo, G., Rosa, A. E. D., Zoccali, R. A., Torre, D. L., D’Arrigo, C., & Spina, E. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00050-2 · Cited by 72
Self-citationPessina, E., Albert, U., Bogetto, F., & Maina, G. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e9b91 · Cited by 71 · cited 1×
“3%) met response criteria of 25% improvement or greater; 2 of them had a reduction 35% or greater in Y-BOCS total score versus baseline.(36) On the basis of these findings, the present study was aimed to test whether aripiprazole would be more effective than placebo on clinical symptoms and cognitive functioning in a…”
ResultA review of antipsychotics in the treatment of obsessive compulsive disorder
Fineberg, N. A., Gale, T. M., & Sivakumaran, T. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881105056640 · Cited by 62 · cited 1×
“Notwithstanding, negative results were reported for risperidone,(20) olanzapine,(21) and quetiapine.(22,23) Antipsychotic augmentation in treatment-resistant OCD is yet well supported by meta-analysis(9,24,25) and by recent reviews,(7,8,10,23,26,27) which tend to confirm the efficacy of this treatment strategy, also p…”
ResultStorch, E. A., Lehmkuhl, H., Geffken, G. R., Touchton, A., & Murphy, T. K. (2008) · Depression and Anxiety · doi:10.1002/da.20303 · Cited by 53
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
Dhansay, Y., Ipser, J., & Stein, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005473 · Cited by 48
Antipsychotic Treatment in Obsessive Compulsive Disorder: A Literature Review
Keuneman, R. J., Pokos, V., Weerasundera, R., & Castle, D. J. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01591.x · Cited by 46 · cited 1×
“Refractory OCD has been found to respond to augmentation with antipsychotic drugs: positive evidence exists for risperidone, olanzapine, and quetiapine, with response rates that range between 33% and 100%.(7) Notwithstanding, negative results were reported for risperidone,(20) olanzapine,(21) and quetiapine.”
BackgroundDahan, L., Husum, H., Mnie‐Filali, O., Arnt, J., Hertel, P., & Haddjeri, N. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089586 · Cited by 46 · cited 1×
“Moreover, it can be argued that 5-HT1A agonistic properties of aripiprazole, by directly and indirectly modulating dopamine neurotransmission, may be beneficial against affective symptoms.(53) On the basis of its unique pattern of D2 functional selectivity and/or combined with actions at other receptors systems (eg, 5…”
BackgroundPharmacological Management of Obsessive-Compulsive Disorder: A Review for Clinicians
McDonough, M., & Kennedy, N. (2002) · Harvard Review of Psychiatry · doi:10.1080/10673220216215 · Cited by 44
Aripiprazole augmentation in treatment-refractory obsessive–compulsive disorder
Sarkar, R., Klein, J., & Krüger, S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1091-1 · Cited by 31
Successful augmentation with aripiprazole in clomipramine-refractory obsessive–compulsive disorder
da Rocha, F. F., & Corrêa, H. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.008 · Cited by 28
Lai, C. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990393 · Cited by 15
Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report
Fornaro, M., Gabrielli, F., Mattei, C., Vinciguerra, V., & Fornaro, P. (2008) · Annals of General Psychiatry · doi:10.1186/1744-859x-7-26 · Cited by 14
Cognitive-enhancing effects of aripiprazole: a case report
Mucci, A., Piegari, G., & Galderisi, S. (2008) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-4-24 · Cited by 12
Successful Aripiprazole Augmentation in a Child With Drug-Resistant Obsessive-Compulsive Disorder
Öztürk, M., & Coşkun, M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bfe068 · Cited by 11
Bruno, A., Riganello, D., & Marino, A. G. (2009) · Cases Journal · doi:10.4076/1757-1626-2-7288 · Cited by 11 · cited 1×
“Several case reports provided further information concerning the effects and the safety of aripiprazole in OCD patients who failed to respond to clomipramine treatment,(28) SRI treatment, in 1 adolescent patient with comorbid chronic tic disorder(33) and in 1 patient with comorbid borderline personality disorder.(34)…”
BackgroundSelf-citation
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“First-line adjunctive therapies: In RCTs, adjunctive aripiprazole was significantly more effective than placebo (Level 1) [750,754], and may be as effective as risperidone [755].”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Hudak, R., & Gannon, J. M. (2022) · Current Clinical Practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Metadata
- Authors
- Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A.
- Affiliations
- University of Messina (IT)
- Corresponding author
- Muscatello, Maria Rosaria A.
- Bruno, Antonio
- Pandolfo, Gianluca
- Micò, Umberto
- Scimeca, Giuseppe
- Romeo, Vincenzo Maria
- Settineri, Salvatore
- Zoccali, Rocco A.
- ORCID
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-04
- Volume
- 31
- Issue
- 2
- Pages
- 174-179
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2013925030
- Cited by
- 122
- References
- 53
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 3 · 2020: 6 · 2019: 7 · 2018: 7 · 2017: 6 · 2016: 13 · 2015: 13 · 2014: 18 · 2013: 7 · 2012: 11
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- aripiprazole, treatment-resistant OCD, serotonin reuptake inhibitors, clomipramine, augmentation therapy, cognitive function, executive function, attentional interference, perseverative errors, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Aripiprazole, Adult, Aged, Clomipramine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Piperazines, Quinolones, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.